^ ab“Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations”. Nature Genetics31 (1): 55–9. (May 2002). doi:10.1038/ng879. PMID11967536.
^Weitzel, Jeffrey N.; Neuhausen, Susan L.; Adamson, Aaron; Tao, Shu; Ricker, Charité; Maoz, Asaf; Rosenblatt, Margalit; Nehoray, Bita et al. (2019-06-17). “Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer”. Cancer125 (16): 2829–2836. doi:10.1002/cncr.32083. ISSN1097-0142. PMID31206626.
^“BRCA1 is regulated by Chk2 in response to spindle damage”. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research1783 (12): 2223–33. (Dec 2008). doi:10.1016/j.bbamcr.2008.08.006. PMID18804494.
^“Polo-like kinase 1 and Chk2 interact and co-localize to centrosomes and the midbody”. The Journal of Biological Chemistry278 (10): 8468–75. (Mar 2003). doi:10.1074/jbc.M211202200. PMID12493754.
^“Mammalian Polo-like kinase 3 (Plk3) is a multifunctional protein involved in stress response pathways”. Oncogene21 (43): 6633–40. (Sep 2002). doi:10.1038/sj.onc.1205850. PMID12242661.
“Checking in on Cds1 (Chk2): A checkpoint kinase and tumor suppressor”. BioEssays24 (6): 502–11. (Jun 2002). doi:10.1002/bies.10101. PMID12111733.
“Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations”. Oncogene25 (43): 5837–45. (Sep 2006). doi:10.1038/sj.onc.1209875. PMID16998498.
“Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216”. Science277 (5331): 1501–5. (Sep 1997). doi:10.1126/science.277.5331.1501. PMID9278512.
“The role of CDP-diacylglycerol synthetase and phosphatidylinositol synthase activity levels in the regulation of cellular phosphatidylinositol content”. The Journal of Biological Chemistry272 (52): 33402–9. (Dec 1997). doi:10.1074/jbc.272.52.33402. PMID9407135.
“A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase”. Current Biology9 (1): 1–10. (Jan 1999). doi:10.1016/S0960-9822(99)80041-4. PMID9889122.
“Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway”. Oncogene18 (28): 4047–54. (Jul 1999). doi:10.1038/sj.onc.1202925. PMID10435585.
“The physical association and phosphorylation of Cdc25C protein phosphatase by Prk”. Oncogene18 (44): 6029–36. (Oct 1999). doi:10.1038/sj.onc.1202983. PMID10557092.